Sanofi reports phase 1/2 mRNA results but withdraws from further COVID19 vaccines

Simon Collins, HIV i-Base

Positive interim results generated significant antibody responses at all studied doses, as proof of concept.

However, clinical efficacy results would require phase 3 studies over the next two years. Instead the company plan to withdraw from further COVID vaccine development and use mRNA technology for vaccines against influenza.


Sanofi press statement. Sanofi announces positive phase 1/2 study interim results for its first mRNA-based vaccine candidate. (28 September 2021).

Links to other websites are current at date of posting but not maintained.